Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
EU Council president: Ukraine should receive binding guarantees - 2Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 3Manual for 6 Busssiness Class Flights
- 4Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
- 5NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- Vote In favor of Your Favored Video Conferencing Administration
- An Extended time of Self-Reflection: Self-awareness through Journaling
- Eco-Accommodating Kitchen Machines: 4 Picks for a Manageable Home
- Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- How effective is the flu shot this year? New report shows promising results
- The biggest black hole breakthroughs of 2025
- 6 Home Cleaning Administrations to Keep Your Home Unblemished
- Instructions to Explore the Universe of Vehicle Leases
- The Manual for Decent European Urban communities in 2024
